Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Austar LifesciencesAULSF 49 3-Year RORE % is -241.18 as of Dec. 2025. GuruFocus rates AULSF with a GF Score™ of 49/100 and a GF Value™ of $0.08 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 777 Medical Devices & Instruments companies, Austar Lifesciences ranks worse than 97.04% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Austar Lifesciences's 3-Year RORE % for the quarter that ended in Dec. 2025 was -241.18%.
The industry rank for Austar Lifesciences's 3-Year RORE % or its related term are showing as below:
AULSF's 3-Year RORE % is ranked worse than 97.04% of 777
companies
in the Medical Devices & Instruments industry
Industry Median: -4.07
vs AULSF: -241.18
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Austar Lifesciences 3-Year RORE % Related Terms
Austar Lifesciences 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Austar Lifesciences's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Austar Lifesciences's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austar Lifesciences 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Austar Lifesciences's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Austar Lifesciences (AULSF) has a 3-Year RORE % of -241.18 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Austar Lifesciences and its competitors. According to the industry distribution chart, Austar Lifesciences ranks #754 out of 777 companies in the Medical Devices & Instruments industry, placing it in the top 97%.
Is Austar Lifesciences' 3-Year RORE % too high?
Austar Lifesciences' current 3-Year RORE % is -241.18. Based on the distribution chart, Austar Lifesciences ranks #754 out of 777 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Austar Lifesciences has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Austar Lifesciences ranks #754 out of 777 companies for 3-Year RORE %. This places Austar Lifesciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Austar Lifesciences and its competitors. Austar Lifesciences's current 3-Year RORE % is -241.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Austar Lifesciences (AULSF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.08, compared to a current price of $0.02 — trading 75% below its estimated fair value. The current 3-Year RORE % is -241.18. Austar Lifesciences' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current 3-Year RORE % is -241.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austar Lifesciences (AULSF) Overvalued in 2026?
Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued.
The current stock price of $0.02 is trading 75% below its estimated GF Value™ of $0.08.
GuruFocus considers Austar Lifesciences to be Possible Value Trap.
Key valuation signals for AULSF:
3-Year RORE %: -241.18
GF Value™: $0.08 vs. price of $0.02 (75% below fair value)
No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
49GF Score
Get the complete analysis for AULSF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AULSF has been successfully added to your 
